WO1994017831A9 - A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration - Google Patents
A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regenerationInfo
- Publication number
- WO1994017831A9 WO1994017831A9 PCT/IB1994/000011 IB9400011W WO9417831A9 WO 1994017831 A9 WO1994017831 A9 WO 1994017831A9 IB 9400011 W IB9400011 W IB 9400011W WO 9417831 A9 WO9417831 A9 WO 9417831A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neurotrophin
- neurite growth
- antibody
- myelin
- subject
- Prior art date
Links
- 230000014511 neuron projection development Effects 0.000 title claims abstract description 95
- 230000017308 neuron projection morphogenesis Effects 0.000 title claims abstract description 90
- 102000004965 antibodies Human genes 0.000 title claims abstract description 45
- 108090001123 antibodies Proteins 0.000 title claims abstract description 45
- 210000003169 Central Nervous System Anatomy 0.000 title claims abstract description 40
- 102100015985 BDNF Human genes 0.000 title claims abstract description 29
- 101700052211 BDNF Proteins 0.000 title claims abstract description 29
- 230000008929 regeneration Effects 0.000 title claims abstract description 29
- 238000011069 regeneration method Methods 0.000 title claims abstract description 28
- 108010072285 growth inhibitory proteins Proteins 0.000 title claims abstract description 13
- 230000001737 promoting Effects 0.000 claims abstract description 11
- 210000004027 cells Anatomy 0.000 claims description 36
- 229940032018 Neurotrophin 3 Drugs 0.000 claims description 22
- 102000004230 Neurotrophin-3 Human genes 0.000 claims description 22
- 108090000742 Neurotrophin-3 Proteins 0.000 claims description 22
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 21
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 21
- 210000002804 Pyramidal Tracts Anatomy 0.000 claims description 18
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 claims description 10
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 claims description 10
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 claims description 10
- 208000009025 Nervous System Disease Diseases 0.000 claims description 8
- 206010029305 Neurological disorder Diseases 0.000 claims description 7
- 210000004102 animal cell Anatomy 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 210000001328 Optic Nerve Anatomy 0.000 claims description 4
- 230000003412 degenerative Effects 0.000 claims description 4
- 230000004380 optic nerve Effects 0.000 claims description 4
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001105 regulatory Effects 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 44
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 43
- 238000000034 method Methods 0.000 description 32
- 230000003902 lesions Effects 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 229920002676 Complementary DNA Polymers 0.000 description 15
- 108020004635 Complementary DNA Proteins 0.000 description 14
- 238000010804 cDNA synthesis Methods 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 210000001519 tissues Anatomy 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 11
- 108020004999 Messenger RNA Proteins 0.000 description 10
- 102000015336 Nerve Growth Factor Human genes 0.000 description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 description 10
- 229920001850 Nucleic acid sequence Polymers 0.000 description 10
- 210000000278 Spinal Cord Anatomy 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 229920002106 messenger RNA Polymers 0.000 description 10
- 229940053128 Nerve Growth Factor Drugs 0.000 description 9
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000002241 Neurites Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 7
- 210000003050 Axons Anatomy 0.000 description 6
- 210000004556 Brain Anatomy 0.000 description 6
- 210000004408 Hybridomas Anatomy 0.000 description 6
- 230000001058 adult Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229920001405 Coding region Polymers 0.000 description 5
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229960000060 monoclonal antibodies Drugs 0.000 description 5
- 210000002569 neurons Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001172 regenerating Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 108060008443 TPPP Proteins 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108091007521 restriction endonucleases Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 3
- 108091006028 chimera Proteins 0.000 description 3
- 230000000295 complement Effects 0.000 description 3
- 238000010192 crystallographic characterization Methods 0.000 description 3
- 102000022270 cytochrome c family Human genes 0.000 description 3
- 108091010617 cytochrome c family Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000727 fraction Substances 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000003966 growth inhibitor Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- 238000007900 DNA-DNA hybridization Methods 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100006003 MT3 Human genes 0.000 description 2
- 210000004126 Nerve Fibers Anatomy 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 108010008267 Nerve Growth Factors Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 229920000272 Oligonucleotide Polymers 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 210000002729 Polyribosomes Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010075381 growth inhibitory factor Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002269 spontaneous Effects 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 240000000244 Crotalaria pallida Species 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N Cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 101710015954 HVA1 Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 108010000345 Immobilized Antibodies Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101700065814 LEA2 Proteins 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 210000003140 Lateral Ventricles Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000000337 Motor Cortex Anatomy 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 210000003497 Sciatic Nerve Anatomy 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000008513 Spinal Cord Injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 240000008529 Triticum aestivum Species 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002165 glioblast Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 108060003552 hemocyanin family Proteins 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 101700001016 mbhA Proteins 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 210000004255 neuroglia Anatomy 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001953 sensory Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001228 trophic Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Definitions
- the present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising
- administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
- the differentiated central nervous system (CNS) of higher vertebrates is capable of only very limited regenerative neurite growth after CNS.
- the differentiated CNS may lack cellular or substrate constituents that are conducive for neurite growth during development
- the factor was estimated to have a molecular weight of about 75,000 by gel filtration with BioGel P-20 with an isoelectric point of 5.8. The factor did not appear to alter the growth rate or morphology of glial cells (C6) or fibroblasts (3T3). In addition, no significant nerve growth inhibitory factor activity was detected towards neuroblastoma cells (Neuro La, NS-20Y and NIE-115) or cloned
- NI-35 35kD
- NI-250 250kD
- Monoclonal antibody IN-1 which neutralizes the activity of these constituents in various systems, has been shown to lead to regeneration of corticospinal tract (CST) axons in young rats over distances of up to 5-11 mm distal to a spinal cord lesion within 2 weeks (Int. Application No. 89912786.4, filed November 2, 1989, by Schwab et al.; U. S. Serial No.
- the present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising
- a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein is administered a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
- monoclonal antibody IN-1 directed against a myelin- associated neurite growth inhibitor, together with a member of the neurotrophin family, (e.g. neurotrophin- 3 (NT-3), brain-derived neurotrophic factor (BDNF), or nerve growth factor (NGF)), was able to promote regeneration of neurites over long distances in the partially transected spinal cord of adult rats. Such distances significantly exceeded the regeneration resulting from antibody without neurotrophin family member.
- NT-3 neurotrophin- 3
- BDNF brain-derived neurotrophic factor
- NGF nerve growth factor
- NT-3 together with antibody directed toward myelin- associated neurite growth inhibitor, may be used to promote regeneration in the CNS.
- Such methods may be directed toward the treatment of neurologic disorders, including trauma as well as degenerative conditions.
- FIGURE 1 Sprouting of lesioned corticospinal tract fibers. The sprouting index was calculated by subtracting the branching index of normal, unlesioned animals. A. Sprouting at the lesion site, 1mm rostral to lesion, and 4mm rostral to lesion,
- FIGURE 2 Millimeters of elongation of
- corticospinal tract fibers (mm from the lesion site) 14-17 days post-lesion in rats intracerebrally
- the neurotrophin family member is NT-3 and the antibody directed toward a myelin-associated neurite growth inhibitory protein is IN-1 (which was raised to PAGE-purified 250,000d fraction from rat spinal cord myelin), as produced by hybridoma cell line IN-1 and deposited with the European Collection of Animal Cell Cultures (ECACC), PHLS Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, United Kingdom, and assigned accession number 88102801.
- ECACC European Collection of Animal Cell Cultures
- the present invention relates to CNS myelin associated neurite growth inhibitory proteins.
- CNS myelin associated inhibitory proteins of the invention may be isolated by first isolating myelin and subsequent purification therefrom. Isolation procedures which may be employed are described more fully in the sections which follow. Alternatively, the CNS myelin associated inhibitory proteins may be obtained from a recombinant expression system (see Section 5.3., infra).
- CNS myelin associated inhibitory proteins can be isolated from the CNS myelin of higher vertebrates including, but not limited to, birds or mammals.
- Myelin can be obtained from the optic nerve or from central nervous system tissue that includes but is not limited to spinal cords or brain stems.
- the tissue may be homogenized using procedures described in the art (Colman et al., 1982, J. Cell Biol. 95:598-608).
- the myelin fraction can be isolated subsequently also using procedures described (Colman et al., 1982,
- the CNS myelin associated inhibitory proteins can be solubilized in detergent (e.g., Nonidet P-40TM, sodium deoxycholate).
- detergent e.g., Nonidet P-40TM, sodium deoxycholate
- the solubilized proteins can subsequently be purified by various procedures known in the art, including but not limited to chromatography (e.g., ion exchange, affinity, and sizing chromatography), centrifugation, electrophoretic procedures, differential solubility, or by any other standard technique for the purification of proteins.
- NI-35 (35 Kd) and NI-250 (250 Kd) myelin-associated neurite growth inhibitory proteins may be utilized (Caroni and
- the CNS myelin associated inhibitory proteins may be isolated and purified using immunological procedures. For example, in one
- the proteins can first be solubilized using detergent (e.g., Nonidet P-40TM, sodium deoxycholate). The proteins may then be isolated by immunoprecipitation with antibodies to the 35 kilodalton and/or the 250 kilodalton proteins.
- detergent e.g., Nonidet P-40TM, sodium deoxycholate.
- the CNS myelin associated inhibitory proteins may be isolated using immunoaffinity
- the neurite growth regulatory factors of the present invention can be characterized by assays based on their physical, immunological, or functional properties.
- putative neurite growth inhibitory factor may be confirmed by testing the ability of the factor to inhibit sprouting or growth of neurites or spreading of 3T3 cells on a polylysine-coated tissue culture dish (Int. Application No. 899127864 filed November 2, 1989 by Schwab et al., U. S. Serial No. 07/401,212 by Schwab et al. filed August 30, 1989, and U. S. Serial No. 07/719,692 by Schwab et al. filed June 24, 1991).
- the half life of the neurite growth regulatory factors in cultured cells can be studied, for example, by use of cycloheximide, an inhibitor of protein synthesis (Vasquez, 1974, FEBS Lett. 40:563-584).
- a physiological receptor for a neurite growth regulatory factor could be identified by assays which detect complex formation with a neurite growth regulatory factor, e.g., by use of affinity
- Electrophoretic techniques such as SDS-polyacryl- amide gel electrophoresis and two-dimensional electro- phoresis can be used to study protein structure.
- amino acid sequences of primary myelin associated inhibitors can be derived by deduction from the DNA sequence if such is available, or
- protein sequences can be further characterized by a hydrophilicity analysis (Hopp and Woods, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828).
- hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the protein (and the corresponding regions of the gene sequence, if available, which encode such regions).
- inhibitor sequence that assume specific secondary structures.
- Other methods of structural analysis can also be employed. These include but are not limited to X-ray crystallography (Engstom, 1974, Biochem. Exp. Biol. 11:7-13) and computer modeling (Fletterick, R. and Zoller, M. (eds.), 1986, Computer Graphics and Molecular Modeling, in Current Communications in
- Any mammalian cell can potentially serve as the nucleic acid source for the molecular cloning of the genes encoding the CNS myelin associated inhibitory proteins, including but not limited to the 35 kD and/or 250 kD myelin associated proteins described in Caroni and Schwab (1988, Neuron 1:85-96).
- the DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a DNA
- library by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired mammalian cell.
- Clones derived from genomic DNA may contain regulatory and intron DNA regions, in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, a given neurite growth regulatory factor gene should be molecularly cloned into a suitable vector for propagation of the gene.
- DNA fragments are generated, some of which will encode the desired neurite growth regulatory factor gene.
- the DNA may be cleaved at specific sites using various restriction enzymes.
- DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated
- identification of the specific DNA fragment containing a neurite growth regulatory factor gene may be accomplished in a number of ways. For example, if an amount of a neurite growth regulatory factor gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, Science
- a portion of a neurite growth regulatory factor amino acid sequence can be used to deduce the DNA sequence, which DNA sequence can then be synthesized as an oligonucleotide for use as a hybridization probe.
- nucleic acid fractions enriched in neurite growth regulatory factor may be used as a probe, as an initial selection procedure.
- a neurite growth regulatory factor gene can also be identified by mRNA selection using nucleic acid hybridization followed by in vitro translation or translation in Xenopus oocytes. In an example of the latter procedure, oocytes are injected with total or size fractionated CNS mRNA populations, and the membrane-associated translation products are screened in a functional assay (3T3 cell spreading).
- DNA fragments can be used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified neurite growth
- Immunoprecipitation analysis or functional assays of the in vitro translation products of the isolated mRNAs identifies the mRNA and, therefore, the cDNA fragments that contain neurite growth regulatory factor sequences.
- An example of such a functional assay involves an assay for nonpermissiveness in which the effect of the various translation products on the spreading of 3T3 cells on a polylysine coated tissue culture dish is observed (see Caroni and Schwab, 1988, J. Cell Biol. 106:1281).
- specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against a neurite growth regulatory factor protein.
- a radiolabelled neurite growth regulatory factor cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabelled mRNA or cDNA may then be used as a probe to identify the neurite growth regulatory factor DNA fragments from among other genomic DNA fragments.
- isolating the neurite growth regulatory factor genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the neurite growth regulatory factor gene. Other methods are possible and within the scope of the invention.
- the identified and isolated gene or cDNA can then be inserted into an appropriate cloning vector.
- vector-host systems known in the art may be used. Possible vectors include, but are not limited to, cosmids, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc.
- the neurite growth regulatory factor gene may be identified and isolated after insertion into a suitable cloning vector, in a "shot gun" approach. Enrichment for a given neurite growth regulatory factor gene, for example, by size fractionation or subtraction of cDNA specific to low neurite growth regulatory factor producers, can be done before insertion into the cloning vector.
- DNA may be inserted into an expression vector system, and the recombinant
- the neurite growth regulatory factor gene may then be detected by functional assays for the neurite growth regulatory factor protein.
- the neurite growth regulatory factor gene is inserted into a cloning vector which can be used to transform, transfect, or infect appropriate host cells so that many copies of the gene sequences are generated. This can be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified.
- any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences.
- the cleaved vector and neurite growth regulatory factor gene may be modified by homopolymeric tailing.
- Identification of the cloned neurite growth regulatory factor gene can be accomplished in a number of ways based on the properties of the DNA itself, or alternatively, on the physical, immunological, or functional properties of its encoded protein.
- the DNA itself may be detected by plaque or colony nucleic acid hybridization to labeled probes (Benton, W. and Davis, R., 1977, Science 196:180;
- a neurite growth regulatory factor gene may be detected by assays based on properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that inhibits in vitro neurite outgrowth. Further, a neurite growth regulatory factor protein may be identified by detecting binding of antibody directed toward the factor to putative neurite growth regulatory factor- synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure.
- ELISA enzyme-linked immunosorbent assay
- transformation of host cells with recombinant DNA molecules that incorporate an isolated neurite growth regulatory factor gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene.
- the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.
- virus expression vectors such as vaccinia virus or adenovirus
- incorporates a neurite growth regulatory factor gene can be modified so that the gene is flanked by virus sequences that allow for genetic recombination in cells infected with the virus so that the gene can be inserted into the viral genome.
- neurite growth regulatory factor DNA- containing clone After the neurite growth regulatory factor DNA- containing clone has been identified, grown, and harvested, its DNA insert may be characterized as described in Section 5.3.4, infra. When the genetic structure of a neurite growth regulatory factor gene is known, it is possible to manipulate the structure for optimal use in the present invention.
- promoter DNA may be ligated 5' of a neurite growth regulatory factor coding sequence, in addition to or replacement of the native promoter to provide for increased expression of the protein.
- the nucleotide sequence coding for a neurite growth regulatory factor protein or a portion thereof can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence.
- the necessary transcription and translation signals can also be supplied by the native neurite growth regulatory factor gene and/or its flanking regions.
- host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus);
- microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA.
- the expression elements of these vectors vary in their strengths and
- any one of a number of suitable transcription and translation elements may be used.
- Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/ translational control signals and the protein coding sequences. These methods may include in vitro
- Expression vectors containing neurite growth regulatory factor gene inserts can be identified by three general approaches: (a) DNA-DNA hybridization, (b) presence or absence of "marker” gene functions, and (c) expression of inserted sequences.
- first approach the presence of a foreign gene
- inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising
- the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if a given neurite growth regulatory factor gene is inserted within the marker gene sequence of the vector, recombinants containing the neurite growth regulatory factor insert can be identified by the absence of the marker gene function.
- recombinant gene functions e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.
- expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based on the physical, immunological, or functional properties of a given neurite growth regulatory factor gene product.
- recombinant expression vectors can be propagated and prepared in quantity.
- the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or
- adenovirus adenovirus
- insect viruses such as baculovirus
- yeast vectors bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
- bacteriophage vectors e.g., lambda
- plasmid and cosmid DNA vectors to name but a few.
- a host cell strain may be chosen which modulates the expression of the inserted
- Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered neurite growth regulatory factor protein may be controlled.
- different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.
- expression in a bacterial system can be used to produce an unglycosylated core protein product.
- Expression in yeast will produce a glycosylated product.
- Expression in mammalian (e.g. COS) cells can be used to ensure "native" glycosylation of the heterologous neurite growth regulatory factor protein.
- different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extends.
- the gene product can be purified as described in
- amino acid sequence of a given neurite growth regulatory factor protein can be deduced from the nucleotide sequence of the cloned gene, allowing the protein, or a fragment thereof, to be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, et al., 1984, Nature 310:105-111).
- such neurite growth regulatory factor proteins include but are not limited to those containing altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change.
- one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration.
- Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
- the nonpolar (hydrophobic) amino acids include
- polar neutral amino acids include glycine, serine,
- the positively charged (basic) amino acids include arginine, lysine, and histidine.
- negatively charged amino acids include aspartic acid and glutamic acid. Also included within the scope of the invention are neurite growth
- regulatory factor proteins which are differentially modified during or after translation, e.g., by
- the regulatory factor gene can be analyzed by various methods known in the art.
- the cloned DNA or CDNA corresponding to a given neurite growth regulatory factor gene can be analyzed by methods including but not limited to Southern hybridization (Southern, 1975, J. Mol. Biol. 98:503- 517), Northern hybridization (Alwine, et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5350-5354; Wahl, et al., 1987, Meth. Enzymol. 152:572-581), restriction endonuclease mapping (Maniatis, et al., 1982,
- DNA sequence analysis can be performed by any techniques known in the art including but not limited to the method of Maxam and Gilbert (1980, Meth.
- Antibodies can be produced which recognize neurite growth regulatory factors or related proteins. Such antibodies can be polyclonal or monoclonal.
- various host animals can be immunized by injection with a neurite growth regulatory factor protein, or a synthetic protein, or fragment thereof, including but not limited to
- adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.
- BCG Bacille Calmette-Guerin
- corynebacterium parvum corynebacterium parvum
- a monoclonal antibody to an epitope of a neurite growth regulatory factor can be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256:495-497), and the more recent human B cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72) and EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
- the monoclonal antibody is produced by cell line IN-1, deposited with ECACC and having accession number
- the monoclonal antibody is produced by cell line IN-2, deposited with the ECACC and having accession number 88102802.
- the monoclonal antibodies for therapeutic use may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies.
- Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:7308-7312; Kozbor et al., 1983, Immunology Today 4:72-79; Olsson et al., 1982, Meth. Enzymol. 92:3-16).
- Chimeric antibody molecules may be prepared containing a mouse antigen- binding domain with human constant regions (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A.
- a molecular clone of an antibody to a neurite growth regulatory factor epitope can be prepared by known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., 1982, Molecular Cloning, A
- nucleic acid sequences which encode a monoclonal antibody molecule, or antigen binding region thereof.
- Antibody molecules may be purified by known techniques, e.g., immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography), or a
- Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
- such fragment's include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, and the 2 Fab or Fab fragments which can be generated by
- the present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising
- administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
- Neurotrophin family members include, but are not limited to, BDNF, as described in PCT Publication No. WO 91/03568 published March 21, 1991 (corresponding to United States Serial No. 07/570,657 by Barde et al.); NT-3, as described in PCT publication No. WO 91/03569 published March 21, 1991 (corresponding to United States Serial No. 07/570,189 by Barde et al.); NGF, as described in United States Patent No. 5,169,762 by Gray et al., issued December 8, 1992; and NT-4, as described in PCT publication No. WO 92/20365.
- BDNF as described in PCT Publication No. WO 91/03568 published March 21, 1991 (corresponding to United States Serial No. 07/570,657 by Barde et al.)
- NT-3 as described in PCT publication No. WO 91/03569 published March 21, 1991 (corresponding to United States Serial No. 07/570,189 by Barde et al.)
- the species of origin of neurotrophin used is the same species as the subject being treated.
- the neurotrophin may be essentially purified and isolated using methods set forth in the cited references or known in the art.
- Antibodies that may be used according to the invention include, but are not limited to, IN-1.
- Methods of promoting central nervous system regeneration may be measured by quantitatively or qualitatively evaluating neurite sprouting or fiber extension or by evaluating recovery of neurological function, using clinical parameters or methods such as those set forth in Section 6, infra.
- Subjects in need of such treatment include human as well as non-human subjects suffering from a
- disorder of the central nervous system including but not limited to a disorder caused by trauma,
- the subject is a human suffering from a neurological disorder that involves the corticospinal tract, including, but not limited to, spinal cord trauma, amyotrophic lateral sclerosis, primary lateral sclerosis, ischemia, stroke, multiple sclerosis, compression lesions, syringomyelia, and multiple systems degeneration.
- a neurological disorder that involves the corticospinal tract, including, but not limited to, spinal cord trauma, amyotrophic lateral sclerosis, primary lateral sclerosis, ischemia, stroke, multiple sclerosis, compression lesions, syringomyelia, and multiple systems degeneration.
- the subject is a human suffering from a neurological disorder that involves the optic nerve.
- treatment refers to the amelioration of symptoms associated with the neurological disorder or a prolongation of survival. In certain instances, a “cure” may be achieved, but the present invention is not so limited.
- neurotrophin and antibody refers to that amount that results in amelioration of symptoms or a prolongation of survival in a subject in need of such treatment.
- the local concentration of neurotrophin may be between about 0.01 and 100 nanograms per gram tissue (net weight) and the local concentration of antibody directed toward myelin-associated neurite growth inhibitory protein may be between about 0.01 and 10 micrograms per gram tissue. Dosage may be determined using standard techniques, e.g. as described in Fingl and Woodbury, 1975, in "The Pharmacological Basis of
- Neurotrophin and antibody may be administered by any suitable route, including, but not limited to, local application via surgery or injection,
- Neurotrophin and antibody may also be administered via a cellular implant that secretes neurotrophin or antibody.
- Neurotrophin and antibody may be administered either together or separately by different routes. It is preferred, however, that concurrent exposure to both neurotrophin and antibody be achieved.
- the present invention also provides for
- compositions comprising neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein in a suitable pharmaceutical carrier.
- the spinal cord of young adult, 4-7 week old rats was lesioned at the mid-thoracic level by bilateral transection of the dorsal half with iridectomy
- Sprouting was quantified on complete serial, parasagital sections by counting all the labelled branches intersecting vertical lines at the lesion site 1 mm rostral and 4 mm rostral to the lesion. The numbers obtained were related to the number of
- Fig. 1a shows that spontaneous sprouting of lesioned adult CST fibers occurred at all three levels.
- a single injection of NT-3 at the time of lesion greatly increased this sprouting. The effect was visible at the lesion site and at 1 mm, but was decreased at 4 mm, perhaps due to a penetration of the factor (Fig. 1a) .
- Control injections with cytochrome C (Fig . 1a) or Ringer's solution alone (Fig. 1b) were indistinguishable.
- NT-3 neurotrophin 3
- CST corticospinal tract
- BDNF brain-derived neurotrophic factor
- Enhancement of the spontaneous regeneration attempts of CNS neurons by specific neurotrophic factors and counteraction of the inhibitory substrate effects of adult CNS tissue may thus cooperate to improve regeneration of lesioned nerve fiber tracts in the CNS.
Abstract
The present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
Description
A COMBINATION OF NEUROTROPHIN AND ANTIBODY DIRECTED
TOWARD MYELIN-ASSOCIATED NEURITE GROWTH INHIBITORY
PROTEIN PROMOTES CENTRAL NERVOUS SYSTEM REGENERATION
1. INTRODUCTION
The present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising
administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
2. BACKGROUND OF THE INVENTION
Cell attachment, cell spreading, cell motility, and, in particular, neurite outgrowth are strongly dependent on cell-substrate interactions (Sanes, 1983, Ann. Rev. Physiol. 45:581-600; Carbonetto et al., 1987, J. Neurosci. 7:610-620). An increasing number of substrate molecules favoring neuroblast migration or neurite outgrowth have been found in central and peripheral nervous tissue (Cornbrooks et al., 1983, Proc. Natl. Acad. Sci. USA 80:3850-3854; Edelman, 1984, Exp. Cell Res. 161:1-16; Liesi, 1985, EMBO J. 4:1163-1170; Chiu, A.Y. et al., 1986, J. Cell Biol. 103:1383-1398; Fischer et al., 1986, J. Neurosci.
6 :605-612; Lindner et al., 1986, Brain Res. 377;298- 304; Mirsky et al., 1986, J. Neurocytol. 15; 799-815; Stallcup et al., 1986, J. Neurosci. 5:1090-1101;
Carbonetto et al., 1987, J. Neurosci. 7:610-620). The appearance of some of these factors can be correlated with specific developmental stages, and, in the peripheral nervous system (PNS), also with denervation (Edelman, 1984, Exp. Cell Res. 161:1-16; Liesi, 1985, EMBO J. 4:1163-1170; Stallcup et al., 1985, J.
Neurosci. 5:109-1101; Daniloff et al., 1986, J. Cell
Biol. 103:929-945; Carbonetto et al., 1987, J.
Neurosci. 7:610-620).
However, the differentiated central nervous system (CNS) of higher vertebrates is capable of only very limited regenerative neurite growth after
lesions. Limited regeneration after lesion has been seen in the retina (McConnell and Berry, 1982, Brain Res. 241:362-365) and in aminergic unmyelinated fiber tracts after chemical (Bjorklund and Stenevi, 1979, Physiol. Rev. 59:62-95) but not mechanical lesions (Bregman, 1987, Dev. Brain Res. 34:265-279). Neurite growth from implanted embryonic CNS tissues in adult rat CNS has been found in some cases to reach up to 14 mm within some gray matter areas, but has not been found to exceed 1 mm within white matter (Nornes et al., 1983, Cell Tissue Res. 230:15-35; Bjorklund and Stenevi, 1979, Physiol. Rev. 59:62-95; Commission, 1984, Neuroscience 12:839-853). On the other hand, extensive regenerative growth has been found in the
CNS of lower vertebrates and in the peripheral nervous system of all vertebrates including man.
Results from transplantation experiments indicate that the lack of regeneration is not an intrinsic property of CNS neurons, as these readily extend processes into implanted peripheral nervous tissue (Benfey and Aguayo, 1982, Nature (London) 296:150-152; Richardson et al., 1984, J. Neurocytol. 13:165-182 and So and Aguayo, 1985, Brain Res. 328:349-354). PNS neurons, however, failed to extend processes into CNS tissue, thus indicating the existence of fundamental differences between the two tissues (Aguayo et al.,
1978, Neurosci. Lett. 9:97-104; Weinberg and Spencer,
1979, Brain Res. 162:273-279).
One major difference between PNS and CNS tissue is the differential distribution of the neurite
outgrowth promoting extracellular matrix component laminin (Liesi, 1985, EMBO J. 4:2505-2511; Carbonetto et al., 1987, J. Neurosci. 2:610-620), but other factors may be involved. Drastic differences have been observed in neurite growth supporting properties of sciatic and optic nerve explants in vitro. in spite of the presence of laminin immunoreactivity in both explants (Schwab and Thoenen, 1985, J. Neurosci.
5:2415-2423).
It has been suggested that the differentiated CNS may lack cellular or substrate constituents that are conducive for neurite growth during development
(Liesi, 1985, EMBO J. 4:2505-2511; and Carbonetto et al, 1987, J. Neurosci. 7:610-620), or it may contain components which are nonpermissive or inhibitory for nerve fiber regeneration (Schwab and Thoenen, 1985, J. Neurosci. 5:2415-2423).
Recently, a growth (cell proliferation) inhibi- tory factor for mouse neuroblastoma cells was
partially purified and characterized from the culture medium of fetal rat glioblasts as well as from C6 rat glioma cells (Sakazaki et al., 1983, Brain Res.
262:125-135). The factor was estimated to have a molecular weight of about 75,000 by gel filtration with BioGel P-20 with an isoelectric point of 5.8. The factor did not appear to alter the growth rate or morphology of glial cells (C6) or fibroblasts (3T3). In addition, no significant nerve growth inhibitory factor activity was detected towards neuroblastoma cells (Neuro La, NS-20Y and NIE-115) or cloned
fibroblasts (3T3).
CNS myelin-associated proteins have been
identified that inhibit neurite outgrowth. Two oligodendrocyte-and myelin-associated membrane
proteins; NI-35 (35kD) and NI-250 (250kD), with potent
inhibitory effects on neurite growth, were identified by in vitro and biochemical studies (Schwab and
Caroni, 1988, J. Neurosci. 8:2381-2393; Caroni and Schwab, 1988, J. Cell. Biol. 106:1281-1288).
Monoclonal antibody IN-1, which neutralizes the activity of these constituents in various systems, has been shown to lead to regeneration of corticospinal tract (CST) axons in young rats over distances of up to 5-11 mm distal to a spinal cord lesion within 2 weeks (Int. Application No. 89912786.4, filed November 2, 1989, by Schwab et al.; U. S. Serial No.
07/401,212 by Schwab et al., filed August 30, 1989; U. S. Serial No. 07/719,692 by Schwab et al., filed June 24, 1991). Such antibody has been used to demonstrate the role of myelin-associated neurite growth
inhibitors in the absence of regeneration of lesioned CNS fiber tracts observed under normal conditions. 3. SUMMARY OF THE INVENTION
The present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising
administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein. It is based, at least in part, on the discovery that monoclonal antibody IN-1, directed against a myelin- associated neurite growth inhibitor, together with a member of the neurotrophin family, (e.g. neurotrophin- 3 (NT-3), brain-derived neurotrophic factor (BDNF), or nerve growth factor (NGF)), was able to promote regeneration of neurites over long distances in the partially transected spinal cord of adult rats. Such distances significantly exceeded the regeneration
resulting from antibody without neurotrophin family member.
In preferred embodiments of the invention, NT-3, together with antibody directed toward myelin- associated neurite growth inhibitor, may be used to promote regeneration in the CNS. Such methods may be directed toward the treatment of neurologic disorders, including trauma as well as degenerative conditions.
4. DESCRIPTION OF THE FIGURES
FIGURE 1. Sprouting of lesioned corticospinal tract fibers. The sprouting index was calculated by subtracting the branching index of normal, unlesioned animals. A. Sprouting at the lesion site, 1mm rostral to lesion, and 4mm rostral to lesion,
following injection of human recombinant NT-3 or cytochrome C (control). B. Sprouting at the lesion site, 1mm rostral to lesion, and 4mm rostral to lesion, following local injection of Ringer's solution (control), BDNF, NGF, or NT-3 in rats intracerebrally carrying hybridoma cells producing monoclonal antibody IN-1.
FIGURE 2. Millimeters of elongation of
corticospinal tract fibers (mm from the lesion site) 14-17 days post-lesion in rats intracerebrally
carrying hybridoma cells producing monoclonal antibody IN-1, following local injection of Ringer's (control), human recombinant BDNF, human recombinant NGF or human recombinant NT-3.
5. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising
administering a therapeutically effective amount of an
essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein. In preferred, specific, non-limiting embodiments of the invention, the neurotrophin family member is NT-3 and the antibody directed toward a myelin-associated neurite growth inhibitory protein is IN-1 (which was raised to PAGE-purified 250,000d fraction from rat spinal cord myelin), as produced by hybridoma cell line IN-1 and deposited with the European Collection of Animal Cell Cultures (ECACC), PHLS Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, United Kingdom, and assigned accession number 88102801.
For purposes of clarity of description, and not by way of limitation, the detailed description of the invention is divided into the following subsections:
(i) isolation and purification of neurite growth regulatory factors;
(ii) protein characterization;
(iii) molecular cloning of genes or gene fragments encoding neurite growth regulatory factors;
(iv) production of antibodies to neurite growth regulatory factors; and
(v) methods of promoting central nervous system regeneration.
5.1. ISOLATION AND PURIFICATION OF NEURITE
GROWTH REGULATORY FACTORS
The present invention relates to CNS myelin associated neurite growth inhibitory proteins. The
CNS myelin associated inhibitory proteins of the invention may be isolated by first isolating myelin and subsequent purification therefrom. Isolation procedures which may be employed are described more
fully in the sections which follow. Alternatively, the CNS myelin associated inhibitory proteins may be obtained from a recombinant expression system (see Section 5.3., infra).
CNS myelin associated inhibitory proteins can be isolated from the CNS myelin of higher vertebrates including, but not limited to, birds or mammals.
Myelin can be obtained from the optic nerve or from central nervous system tissue that includes but is not limited to spinal cords or brain stems. The tissue may be homogenized using procedures described in the art (Colman et al., 1982, J. Cell Biol. 95:598-608). The myelin fraction can be isolated subsequently also using procedures described (Colman et al., 1982,
supra).
In one embodiment of the invention the CNS myelin associated inhibitory proteins can be solubilized in detergent (e.g., Nonidet P-40™, sodium deoxycholate). The solubilized proteins can subsequently be purified by various procedures known in the art, including but not limited to chromatography (e.g., ion exchange, affinity, and sizing chromatography), centrifugation, electrophoretic procedures, differential solubility, or by any other standard technique for the purification of proteins.
In specific embodiments, the NI-35 (35 Kd) and NI-250 (250 Kd) myelin-associated neurite growth inhibitory proteins may be utilized (Caroni and
Schwab, 1988, J. Cell Biol. 106:1281-1288; Schwab and Caroni, 1988, J. Neurosci. 8:2381-2393; Caroni and Schwab, 1988, Neuron 1:85-96).
Alternatively, the CNS myelin associated inhibitory proteins may be isolated and purified using immunological procedures. For example, in one
embodiment of the invention, the proteins can first be
solubilized using detergent (e.g., Nonidet P-40™, sodium deoxycholate). The proteins may then be isolated by immunoprecipitation with antibodies to the 35 kilodalton and/or the 250 kilodalton proteins.
Alternatively, the CNS myelin associated inhibitory proteins may be isolated using immunoaffinity
chromatography in which the proteins are applied to an antibody column in solubilized form.
5.2. PROTEIN CHARACTERIZATION
The neurite growth regulatory factors of the present invention can be characterized by assays based on their physical, immunological, or functional properties.
For example, the functional activity of a
putative neurite growth inhibitory factor may be confirmed by testing the ability of the factor to inhibit sprouting or growth of neurites or spreading of 3T3 cells on a polylysine-coated tissue culture dish (Int. Application No. 899127864 filed November 2, 1989 by Schwab et al., U. S. Serial No. 07/401,212 by Schwab et al. filed August 30, 1989, and U. S. Serial No. 07/719,692 by Schwab et al. filed June 24, 1991). The half life of the neurite growth regulatory factors in cultured cells can be studied, for example, by use of cycloheximide, an inhibitor of protein synthesis (Vasquez, 1974, FEBS Lett. 40:563-584). In other experiments, a physiological receptor for a neurite growth regulatory factor could be identified by assays which detect complex formation with a neurite growth regulatory factor, e.g., by use of affinity
chromatography with immobilized neurite growth
regulatory factor, binding to a labeled neurite growth regulatory factor followed by cross-linking and immunoprecipitation, etc.
Electrophoretic techniques such as SDS-polyacryl- amide gel electrophoresis and two-dimensional electro- phoresis can be used to study protein structure.
Other techniques which can be used include but are not limited to peptide mapping, isoelectric focusing, and chromatographic techniques.
The amino acid sequences of primary myelin associated inhibitors can be derived by deduction from the DNA sequence if such is available, or
alternatively, by direct sequencing of the protein, e.g. , with an automated amino acid sequencer. The protein sequences can be further characterized by a hydrophilicity analysis (Hopp and Woods, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828). A
hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the protein (and the corresponding regions of the gene sequence, if available, which encode such regions).
Secondary structural analysis (Chou and Fasman, 1974, Biochemistry 13:222) can also be done, to identify regions of the CNS myelin associated
inhibitor sequence that assume specific secondary structures. Other methods of structural analysis can also be employed. These include but are not limited to X-ray crystallography (Engstom, 1974, Biochem. Exp. Biol. 11:7-13) and computer modeling (Fletterick, R. and Zoller, M. (eds.), 1986, Computer Graphics and Molecular Modeling, in Current Communications in
Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).
5.3. MOLECULAR CLONING OF GENES OR GENE FRAGMENTS ENCODING NEURITE GROWTH REGULATORY FACTORS
5.3.1. ISOLATION AND CLONING OF THE NEURITE
GROWTH REGULATORY FACTOR GENES
Any mammalian cell can potentially serve as the nucleic acid source for the molecular cloning of the genes encoding the CNS myelin associated inhibitory proteins, including but not limited to the 35 kD and/or 250 kD myelin associated proteins described in Caroni and Schwab (1988, Neuron 1:85-96).
The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a DNA
"library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired mammalian cell. (See, for example, Maniatis et al., 1982, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd.,
Oxford, U.K., Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions, in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, a given neurite growth regulatory factor gene should be molecularly cloned into a suitable vector for propagation of the gene.
In the molecular cloning of a neurite growth regulatory factor gene from genomic DNA, DNA fragments are generated, some of which will encode the desired neurite growth regulatory factor gene. The DNA may be cleaved at specific sites using various restriction enzymes.
Alternatively, one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication.
The linear DNA fragments can then be separated
according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.
Once the DNA fragments are generated, identification of the specific DNA fragment containing a neurite growth regulatory factor gene may be accomplished in a number of ways. For example, if an amount of a neurite growth regulatory factor gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, Science
196:180; Grunstein and Hogness, 1975, Proc. Natl.
Acad. Sci. U.S.A. 72:3961-3965). For example, in a preferred embodiment, a portion of a neurite growth regulatory factor amino acid sequence can be used to deduce the DNA sequence, which DNA sequence can then be synthesized as an oligonucleotide for use as a hybridization probe.
Alternatively, if a purified neurite growth regulatory factor probe is unavailable, nucleic acid fractions enriched in neurite growth regulatory factor may be used as a probe, as an initial selection procedure.
It is also possible to identify an appropriate neurite growth regulatory factor-encoding fragment by restriction enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection on the basis of the properties of the gene, or the physical, chemical, or immunological properties of its expressed product, as described supra, can be employed after the initial selection.
A neurite growth regulatory factor gene can also be identified by mRNA selection using nucleic acid hybridization followed by in vitro translation or translation in Xenopus oocytes. In an example of the latter procedure, oocytes are injected with total or size fractionated CNS mRNA populations, and the membrane-associated translation products are screened in a functional assay (3T3 cell spreading). Pread- sorption of the RNA with complementary DNA (cDNA) pools leading to the absence of expressed inhibitory factors indicates the presence of the desired cDNA. Reduction of pool size will finally lead to isolation of a single cDNA clone. In an alternative procedure, DNA fragments can be used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified neurite growth
regulatory factor DNA, or DNA that has been enriched for neurite growth regulatory factor sequences.
Immunoprecipitation analysis or functional assays of the in vitro translation products of the isolated mRNAs identifies the mRNA and, therefore, the cDNA fragments that contain neurite growth regulatory factor sequences. An example of such a functional assay involves an assay for nonpermissiveness in which the effect of the various translation products on the spreading of 3T3 cells on a polylysine coated tissue culture dish is observed (see Caroni and Schwab, 1988, J. Cell Biol. 106:1281). In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against a neurite growth regulatory factor protein. A radiolabelled neurite growth regulatory factor cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabelled mRNA or cDNA may then be used as a probe
to identify the neurite growth regulatory factor DNA fragments from among other genomic DNA fragments.
Alternatives to isolating the neurite growth regulatory factor genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the neurite growth regulatory factor gene. Other methods are possible and within the scope of the invention.
The identified and isolated gene or cDNA can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, cosmids, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc.
In an alternative embodiment, the neurite growth regulatory factor gene may be identified and isolated after insertion into a suitable cloning vector, in a "shot gun" approach. Enrichment for a given neurite growth regulatory factor gene, for example, by size fractionation or subtraction of cDNA specific to low neurite growth regulatory factor producers, can be done before insertion into the cloning vector. In another embodiment, DNA may be inserted into an expression vector system, and the recombinant
expression vector containing a neurite growth
regulatory factor gene may then be detected by functional assays for the neurite growth regulatory factor protein.
The neurite growth regulatory factor gene is inserted into a cloning vector which can be used to transform, transfect, or infect appropriate host cells so that many copies of the gene sequences are generated. This can be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and neurite growth regulatory factor gene may be modified by homopolymeric tailing.
Identification of the cloned neurite growth regulatory factor gene can be accomplished in a number of ways based on the properties of the DNA itself, or alternatively, on the physical, immunological, or functional properties of its encoded protein. For example, the DNA itself may be detected by plaque or colony nucleic acid hybridization to labeled probes (Benton, W. and Davis, R., 1977, Science 196:180;
Grunstein, M. and Hogness, D., 1975, Proc. Natl.
Acad. Sci. U.S.A. 72:3961). Alternatively, the presence of a neurite growth regulatory factor gene may be detected by assays based on properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that inhibits in vitro neurite outgrowth. Further, a neurite growth regulatory factor protein may be identified by
detecting binding of antibody directed toward the factor to putative neurite growth regulatory factor- synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure.
In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate an isolated neurite growth regulatory factor gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.
If the ultimate goal is to insert the gene into virus expression vectors such as vaccinia virus or adenovirus, the recombinant DNA molecule that
incorporates a neurite growth regulatory factor gene can be modified so that the gene is flanked by virus sequences that allow for genetic recombination in cells infected with the virus so that the gene can be inserted into the viral genome.
After the neurite growth regulatory factor DNA- containing clone has been identified, grown, and harvested, its DNA insert may be characterized as described in Section 5.3.4, infra. When the genetic structure of a neurite growth regulatory factor gene is known, it is possible to manipulate the structure for optimal use in the present invention. For
example, promoter DNA may be ligated 5' of a neurite growth regulatory factor coding sequence, in addition to or replacement of the native promoter to provide for increased expression of the protein. Many
manipulations are possible, and within the scope of the present invention.
5.3.2. EXPRESSION OF THE CLONED NEURITE
GROWTH REGULATORY FACTOR GENES
The nucleotide sequence coding for a neurite growth regulatory factor protein or a portion thereof, can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcription and translation signals can also be supplied by the native neurite growth regulatory factor gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus);
microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. The expression elements of these vectors vary in their strengths and
specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.
Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/ translational control signals and the protein coding sequences. These methods may include in vitro
recombinant DNA and synthetic techniques and in vivo recombinations (genetic recombination).
Expression vectors containing neurite growth regulatory factor gene inserts can be identified by three general approaches: (a) DNA-DNA hybridization, (b) presence or absence of "marker" gene functions,
and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene
inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising
sequences that are homologous to an inserted neurite growth regulatory factor gene. In the second
approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if a given neurite growth regulatory factor gene is inserted within the marker gene sequence of the vector, recombinants containing the neurite growth regulatory factor insert can be identified by the absence of the marker gene function. In the third approach, recombinant
expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based on the physical, immunological, or functional properties of a given neurite growth regulatory factor gene product.
Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or
adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
In addition, a host cell strain may be chosen which modulates the expression of the inserted
sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered neurite growth regulatory factor protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian (e.g. COS) cells can be used to ensure "native" glycosylation of the heterologous neurite growth regulatory factor protein. Furthermore, different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extends.
5.3.3. IDENTIFICATION AND PURIFICATION OF
THE EXPRESSED GENE PRODUCT
Once a recombinant which expresses a given neurite growth regulatory factor gene is identified, the gene product can be purified as described in
Section 5.1, supra, and analyzed as described in
Section 5.2, supra.
The amino acid sequence of a given neurite growth regulatory factor protein can be deduced from the nucleotide sequence of the cloned gene, allowing the protein, or a fragment thereof, to be synthesized by
standard chemical methods known in the art (e.g., see Hunkapiller, et al., 1984, Nature 310:105-111).
In particular embodiments of the present invention, such neurite growth regulatory factor proteins, whether produced by recombinant DNA techniques or by chemical synthetic methods, include but are not limited to those containing altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include
alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. The polar neutral amino acids include glycine, serine,
threonine, cysteine, tyrosine, asparagine, and
glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The
negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Also included within the scope of the invention are neurite growth
regulatory factor proteins which are differentially modified during or after translation, e.g., by
glycosylation, proteolytic cleavage, etc.
5.3.4. CHARACTERIZATION OF THE NEURITE
GROWTH REGULATORY FACTOR GENES
The structure of a given neurite growth
regulatory factor gene can be analyzed by various methods known in the art.
The cloned DNA or CDNA corresponding to a given neurite growth regulatory factor gene can be analyzed by methods including but not limited to Southern hybridization (Southern, 1975, J. Mol. Biol. 98:503- 517), Northern hybridization (Alwine, et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5350-5354; Wahl, et al., 1987, Meth. Enzymol. 152:572-581), restriction endonuclease mapping (Maniatis, et al., 1982,
Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), and DNA sequence analysis.
DNA sequence analysis can be performed by any techniques known in the art including but not limited to the method of Maxam and Gilbert (1980, Meth.
Enzymol. 65:499-560), the Sanger dideoxy method
(Sanger, et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467), or use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA).
5.4. PRODUCTION OF ANTIBODIES TO NEURITE GROWTH REGULATORY FACTORS
Antibodies can be produced which recognize neurite growth regulatory factors or related proteins. Such antibodies can be polyclonal or monoclonal.
Various procedures known in the art may be used for the production of polyclonal antibodies to
epitopes of a given neurite growth regulatory factor. For the production of antibody, various host animals can be immunized by injection with a neurite growth regulatory factor protein, or a synthetic protein, or fragment thereof, including but not limited to
rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such
as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.
A monoclonal antibody to an epitope of a neurite growth regulatory factor can be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256:495-497), and the more recent human B cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72) and EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
In preferred embodiments of the invention, the monoclonal antibody is produced by cell line IN-1, deposited with ECACC and having accession number
88102801. In additional embodiments, the monoclonal antibody is produced by cell line IN-2, deposited with the ECACC and having accession number 88102802.
The monoclonal antibodies for therapeutic use may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies. Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:7308-7312; Kozbor et al., 1983, Immunology Today 4:72-79; Olsson et al., 1982, Meth. Enzymol. 92:3-16). Chimeric antibody molecules may be prepared containing a mouse antigen- binding domain with human constant regions (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851, Takeda et al., 1985, Nature 314:452).
A molecular clone of an antibody to a neurite growth regulatory factor epitope can be prepared by known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., 1982, Molecular Cloning, A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) may be used to construct nucleic acid sequences which encode a monoclonal antibody molecule, or antigen binding region thereof.
Antibody molecules may be purified by known techniques, e.g., immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography), or a
combination thereof, etc.
Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
For example, such fragment's include but are not limited to: the F(ab')2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragment, and the 2 Fab or Fab fragments which can be generated by
treating the antibody molecule with papain and a reducing agent.
5.5. METHODS OF PROMOTING CENTRAL NERVOUS SYSTEM REGENERATION
The present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising
administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
Neurotrophin family members include, but are not limited to, BDNF, as described in PCT Publication No. WO 91/03568 published March 21, 1991 (corresponding to
United States Serial No. 07/570,657 by Barde et al.); NT-3, as described in PCT publication No. WO 91/03569 published March 21, 1991 (corresponding to United States Serial No. 07/570,189 by Barde et al.); NGF, as described in United States Patent No. 5,169,762 by Gray et al., issued December 8, 1992; and NT-4, as described in PCT publication No. WO 92/20365.
Preferably, the species of origin of neurotrophin used is the same species as the subject being treated. The neurotrophin may be essentially purified and isolated using methods set forth in the cited references or known in the art.
Antibodies that may be used according to the invention include, but are not limited to, IN-1.
Methods of promoting central nervous system regeneration may be measured by quantitatively or qualitatively evaluating neurite sprouting or fiber extension or by evaluating recovery of neurological function, using clinical parameters or methods such as those set forth in Section 6, infra.
Subjects in need of such treatment include human as well as non-human subjects suffering from a
disorder of the central nervous system including but not limited to a disorder caused by trauma,
infarction, infection, embolism, malignancy, metabolic defect, exposure to a toxin, degenerative disorder, etc. In a preferred, nonlimiting embodiment of the invention, the subject is a human suffering from a neurological disorder that involves the corticospinal tract, including, but not limited to, spinal cord trauma, amyotrophic lateral sclerosis, primary lateral sclerosis, ischemia, stroke, multiple sclerosis, compression lesions, syringomyelia, and multiple systems degeneration. In another preferred,
nonlimiting embodiment of the invention, the subject
is a human suffering from a neurological disorder that involves the optic nerve.
The term "treatment", as used herein, refers to the amelioration of symptoms associated with the neurological disorder or a prolongation of survival. In certain instances, a "cure" may be achieved, but the present invention is not so limited.
A therapeutically effective amount of
neurotrophin and antibody refers to that amount that results in amelioration of symptoms or a prolongation of survival in a subject in need of such treatment. In various embodiments of the invention, the local concentration of neurotrophin may be between about 0.01 and 100 nanograms per gram tissue (net weight) and the local concentration of antibody directed toward myelin-associated neurite growth inhibitory protein may be between about 0.01 and 10 micrograms per gram tissue. Dosage may be determined using standard techniques, e.g. as described in Fingl and Woodbury, 1975, in "The Pharmacological Basis of
Therapeutics," Fifth Edition, Goodman and Gilman, eds., Macmillin Publ., N. Y., pp. 1-46.
Neurotrophin and antibody may be administered by any suitable route, including, but not limited to, local application via surgery or injection,
intravenous, intrathecal, subcutaneous, or
intramuscular routes. Neurotrophin and antibody may also be administered via a cellular implant that secretes neurotrophin or antibody. Neurotrophin and antibody may be administered either together or separately by different routes. It is preferred, however, that concurrent exposure to both neurotrophin and antibody be achieved.
The present invention also provides for
pharmaceutical compositions comprising neurotrophin
and antibody directed toward myelin-associated neurite growth inhibitory protein in a suitable pharmaceutical carrier.
6. EXAMPLE: NEUROTROPHIN 3 (NT-3) ENHANCES
REGENERATIVE SPROUTING OF THE LESIONED CORTICOSPINAL TRACT
6.1. MATERIALS AND METHODS
The spinal cord of young adult, 4-7 week old rats was lesioned at the mid-thoracic level by bilateral transection of the dorsal half with iridectomy
scissors. Recombinant human neurotrophic factors NGF, BDNF, or NT-3 (300 - 500 ng in 0.3-0.5 μl) were injected with a glass capillary immediately rostral to the lesion into the spinal cord. Controls received equivalent amounts of cytochrome C or vehicle
(Ringer's solution). In some of the rats hybridoma cells producing the monoclonal antibody (mAB)IN-l were intracerebrally injected into the left frontal cortex and lateral ventricle. This antibody was raised against the PAGE-purified 250,000 protein fraction from rat spinal cord myelin, a preparation which was highly enriched in neurite growth inhibitory activity. The antibodies secreted by the locally formed tumor reached the spinal cord via the cerebrospinal fluid. 14-17 days later, the corticospinal tract (CST) axons were traced by anterograde transport of wheat germ agglutinin-horseradish peroxidase (WGA-HRP) injected into the right sensory motor cortex. Rats were fixed and processed for HRP histochemistry one day later.
6.2. RESULTS
Sprouting was quantified on complete serial, parasagital sections by counting all the labelled branches intersecting vertical lines at the lesion
site 1 mm rostral and 4 mm rostral to the lesion. The numbers obtained were related to the number of
labelled axons within the compact CST; the value for the normal collateral branching present in unlesioned animals was substracted in order to get a sprouting index.
Fig. 1a shows that spontaneous sprouting of lesioned adult CST fibers occurred at all three levels. A single injection of NT-3 at the time of lesion greatly increased this sprouting. The effect was visible at the lesion site and at 1 mm, but was decreased at 4 mm, perhaps due to a penetration of the factor (Fig. 1a) . Control injections with cytochrome C (Fig . 1a) or Ringer's solution alone (Fig. 1b) were indistinguishable.
Comparison of three members of the neurotrophin family showed very significant differences (Fig. 1b). Whereas BDNF had little effect, sprouting seemed to be enhanced in the NGF-treated rats without, however, reaching significant levels (except at 4 mm). In contrast, a highly significant enhancement of
sprouting was seen with NT-3. The number of labelled axons in the CST varied from animal to animal.
However, the values for all the groups overlapped and the mean numbers for each treatment group were very similar (70-125 labelled axons per CST). This result shows that the neuronal metabolism, as shown by anterograde transport of the lectin coupled HRP
(probably reflecting newly synthesized glycoproteins and glycolipids), was not affected by the trophic factor treatment.
The elongation of CST axons was determined on the same serial parasagittal sections for all the groups on number coded slides. The distance of the most caudal labelled fibers was measured (mm from the
lesion site) and is shown in Fig. 2. Regeneration distances of 0.2-0.7 mm correspond to the mean length of sprouts growing towards and around the lesion site. In presence of NT-3, i.e. under conditions of strongly stimulated sprouting, no elongation greater than 0.7 mm was observed in the presence of a control antibody. In contrast, 7 of 16 rats showed elongation over much longer distances with the combined treatment of NT-3 and mAB IN-1. In fact, this group contained animals showing the longest regenerations we have ever
observed. In these rats, the regenerating fibers reached the lower lumbar and sacral spinal cord.
Regeneration over distances of several millimeters were also obtained by combinations of mAB IN-1 with BDNF or NGF (Fig. 2).
6.3. DISCUSSION
The foregoing data shows that the local injection of neurotrophin 3 (NT-3) into the partially transacted spinal cord of adult rats increases the regenerative sprouting of the largest descending fiber tract, the corticospinal tract (CST). Among the related NGF family members, brain-derived neurotrophic factor (BDNF) had little effect, whereas NGF showed an intermediate effect on sprouting. In spite of this stimulation, only short regeneration distances (about 1 mm) from the lesion site were observed. In
contrast, the application of a monoclonal antibody (IN-l) raised against the myelin-associated neurite growth inhibitors alone or in combination with neurotrophic factors resulted in long distance regeneration (2-20 mm) of a small percentage of CST fibers.
Enhancement of the spontaneous regeneration attempts of CNS neurons by specific neurotrophic factors and counteraction of the inhibitory substrate effects of
adult CNS tissue may thus cooperate to improve regeneration of lesioned nerve fiber tracts in the CNS.
Various references are cited herein which are hereby incorporated by reference in their entirety.
Claims
1. A method of promoting central nervous system regeneration in a subject in need of such treatment comprising administering to the subject a
therapeutically effective amount of a purified and isolated neurotrophin family member together with an antibody that specifically binds a myelin-associated neurite growth inhibitory protein.
2 . The method of claim 1 in which the subject in need of such treatment suffers from a neurological disorder involving the corticospinal tract.
3. The method of claim 2 in which the
neurological disorder is a degenerative condition.
4. The method of claim 1 in which the subject in need of such treatment suffers from a neurological disorder that is a degenerative condition.
5. The method of claim 3 in which the
neurological disorder is amyotrophic lateral
sclerosis.
6. The method of claim 1, 2, 3, 4, or 5 in which the neurotrophin family member is neurotrophin- 3.
7. The method of claim 1, 2, 3, 4, or 5 in which the antibody is monoclonal antibody IN-1, as produced by cell line IN-1, deposited with the
European Collection of Animal Cell Cultures and assigned accession number 88102801.
8. The method of claim 1, 2, 3, 4, or 5 in which the neurotrophin family member is neurotrophin-3 and the antibody is monoclonal antibody IN-1, as produced by cell line IN-1, deposited with the
European Collection of Animal Cell Cultures and assigned accession number 88102801.
9. A pharmaceutical composition comprising a purified and isolated neurotrophin family member and an antibody that specifically binds a myelin- associated neurite growth inhibitory protein in a suitable pharmaceutical carrier.
10. The pharmaceutical composition of claim 9 in which the neurotrophin family member is neurotrophin- 3.
11. The pharmaceutical composition of claim 9 in which the antibody is monoclonal antibody IN-1, as produced by cell line IN-1, deposited with the
European Collection of Animal Cell Cultures and assigned accession number 88102801.
12. The pharmaceutical composition of claim 9 in which the neurotrophin family member is neurotrophin-3 and the antibody is monoclonal antibody IN-1, as produced by cell line IN-1, deposited with the
European Collection of Animal Cell Cultures and assigned accession number 88102801.
13. A method of promoting corticospinal tract regeneration in a subject in need of such treatment comprising administering to the subject a
therapeutically effective amount of purified and isolated neurotrophin-3 together with monoclonal antibody IN-1, as produced by cell line IN-1,
deposited with the European Collection of Animal Cell Cultures and assigned accession number 88102801.
14. The method of claim 13 in which the subject suffers from amyotrophic lateral sclerosis.
15. The method of claim 1 in which the central nervous system regeneration is optic nerve
regeneration.
16. The method of claim 15 in which the
neurotrophin family member is brain-derived
neurotrophic factor.
17. The method of claim 16 in which the antibody is monoclonal antibody IN-1, as produced by cell line IN-1, deposited with the European Collection of Animal Cell Cultures and assigned accession number 8810280.1.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002117889A CA2117889A1 (en) | 1993-02-11 | 1994-02-08 | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
EP94905206A EP0634939A1 (en) | 1993-02-11 | 1994-02-08 | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
AU58913/94A AU5891394A (en) | 1993-02-11 | 1994-02-08 | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
JP6517851A JPH07509002A (en) | 1993-02-11 | 1994-02-08 | Combination of neurotrophins and antibodies against myelin-related axonal growth inhibitory protein promotes central nervous system regeneration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1635493A | 1993-02-11 | 1993-02-11 | |
US08/016,354 | 1993-02-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994017831A1 WO1994017831A1 (en) | 1994-08-18 |
WO1994017831A9 true WO1994017831A9 (en) | 1994-09-29 |
Family
ID=21776697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1994/000011 WO1994017831A1 (en) | 1993-02-11 | 1994-02-08 | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0634939A1 (en) |
JP (1) | JPH07509002A (en) |
AU (1) | AU5891394A (en) |
CA (1) | CA2117889A1 (en) |
IL (1) | IL108600A0 (en) |
WO (1) | WO1994017831A1 (en) |
ZA (1) | ZA94887B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020928A1 (en) | 1995-12-06 | 1997-06-12 | Sumitomo Pharmaceuticals Company, Limited | Novel semaphorin z and gene encoding the same |
CA2265500C (en) | 1996-09-11 | 2010-04-13 | Sumitomo Pharmaceuticals Co., Ltd. | Novel semaphorin gene: semaphorin y |
EP0945505A4 (en) | 1996-10-09 | 2002-11-27 | Sumitomo Pharma | Novel semaphorin gene: semaphorin w |
CA2190418A1 (en) * | 1996-11-15 | 1998-05-15 | Zhi-Cheng Xiao | Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof |
AU4964097A (en) | 1996-11-15 | 1998-06-10 | Sumitomo Pharmaceuticals Company, Limited | Novel semaphorin genes (i) |
EP0878480A1 (en) | 1997-05-14 | 1998-11-18 | H.W. Prof. Dr. Müller | A method for the improvement of neuronal regeneration |
SE9901428D0 (en) * | 1999-04-21 | 1999-04-21 | Karolinska Innovations Ab | Amphibodies |
NZ520065A (en) | 2000-01-12 | 2006-02-24 | Univ Yale | Nogo receptor-mediated blockade of axonal growth |
DK1325130T3 (en) | 2000-10-06 | 2010-05-25 | Univ Yale | Nogo Receptor Homologs |
US8912144B2 (en) | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
JP2007514748A (en) * | 2003-12-16 | 2007-06-07 | チルドレンズ メディカル センター コーポレーション | Methods for treating neurological disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0396719B1 (en) * | 1988-11-04 | 1995-07-05 | Erziehungsdirektion Of The Canton Zurich | Neurite growth regulatory factors |
IL95511A (en) * | 1989-08-30 | 2000-10-31 | Max Planck Gesellschaft | Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor |
AU2152092A (en) * | 1991-06-24 | 1993-01-25 | Erziehungsdirektion Of The Canton Zurich | Neurite growth regulatory factors |
JP2008027291A (en) * | 2006-07-24 | 2008-02-07 | Hitachi Ltd | Storage device and data protecting method |
-
1994
- 1994-02-08 EP EP94905206A patent/EP0634939A1/en not_active Withdrawn
- 1994-02-08 WO PCT/IB1994/000011 patent/WO1994017831A1/en not_active Application Discontinuation
- 1994-02-08 AU AU58913/94A patent/AU5891394A/en not_active Abandoned
- 1994-02-08 CA CA002117889A patent/CA2117889A1/en not_active Abandoned
- 1994-02-08 JP JP6517851A patent/JPH07509002A/en active Pending
- 1994-02-09 IL IL10860094A patent/IL108600A0/en unknown
- 1994-02-09 ZA ZA94887A patent/ZA94887B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6291247B1 (en) | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity | |
Acheson et al. | Detection of brain-derived neurotrophic factor-like activity in fibroblasts and Schwann cells: inhibition by antibodies to NGF | |
RU2128226C1 (en) | Isolated dna fragment, a method of preparing a recombinant protein exhibiting neurotropic activity, protein nt-3 and a pharmaceutical composition | |
US9044428B2 (en) | Neuritogenic peptides | |
US20090124543A1 (en) | Activity dependent neurotrophic factor iii (adnf iii) | |
US8618060B2 (en) | Metallothionein-derived peptide fragments | |
JP2006087434A (en) | Novel neurotrophic factor | |
AU652537B2 (en) | Neurite growth regulatory factors | |
JP4638027B2 (en) | Heparin binding growth factor (HBGF) polypeptide | |
CA2079218A1 (en) | Epithelins: novel cysteine-rich growth modulating proteins | |
WO1998022499A9 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
WO1998022499A2 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
WO1994017831A9 (en) | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration | |
JPH07506488A (en) | Recombinant stimulator of neu receptor | |
CA2279231C (en) | Activity dependent neurotrophic factor iii (adnf iii) | |
EP0634939A1 (en) | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration | |
BRPI0614419A2 (en) | gdnf-derived peptides | |
JPH08500246A (en) | Cell growth inhibitor, preparation and use thereof | |
US5504197A (en) | DNA encoding neurotrophic growth factors | |
US20030203383A1 (en) | Novel neurotrophic factor immunoassays | |
EP2121740A2 (en) | Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins | |
EP0753013A1 (en) | Neurotrophin-6: a new member of the neurotrophin family | |
CA2221391A1 (en) | Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof | |
US20130171139A1 (en) | Ncam-vase and neurodegeneration | |
MXPA00001234A (en) | Heparin-binding growth factor (hbgf) polypeptides |